Related Experiment Video
Updated: Aug 18, 2026

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome
Published on: October 2, 2018
Revisit of metformin treatment in polycystic ovarian syndrome
P M Lam1, L P Cheung, C Haines
1Departments of Obstetrics and Gynecology, Prince of Wales Hospital, Shatin, Hong Kong SAR, China.
Abstract:
Polycystic ovary syndrome (PCOS) is a common endocrinopathy in women; its traditional pharmacological therapy mainly addresses short-term symptom control and does not correct the associated long-term metabolic risks. Recently, there has been increasing evidence that insulin resistance has an important implication in the pathogenesis of PCOS and that insulin-sensitizing drugs are a useful therapeutic approach. Therefore this review aims to discuss the current evidence on the use of metformin, a commonly used insulin-sensitizing agent, in treating both the short-term and the long-term problems of women with PCOS.
Related Concept Videos
Oogenesis
Diabetes Mellitus: Type 2 and Gestational
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones

